Sviridov D D, Misharin A Y, Safonova I G, Bushmakina N G, Repin V S, Smirnov V N
Institute of Experimental Cardiology, USSR Cardiology Research Center, Moscow.
Biochim Biophys Acta. 1988 Nov 4;963(1):119-25. doi: 10.1016/0005-2760(88)90344-x.
The binding of human high-density lipoprotein (HDL3), apolipoprotein A-I (apoA-I) and recombinants of apoA-I with cholesterol and/or dimyristoylphosphatidylcholine (DMPC) to the HDL receptor on isolated human small intestine epithelial cells was studied. ApoA-I competed for 125I-labelled HDL3 binding sites less effectively than HDL3, and a lower amount of 125I-labelled apoA-I than 125I-HDL3 was bound to cells. The apoA-I/DMPC recombinant competed for 125I-HDL3 binding sites nearly as well as HDL3, and 125I-apoA-I/DMPC recombinant bound to cells with at least the same efficiency as 125I-HDL3. The apoA-I/DMPC/cholesterol recombinant failed to compete for 125I-HDL3 binding sites, and the 125I-apoA-I/DMPC/cholesterol complex binding to cells was several-fold lower than that of other particles. All particles bound to cells with similar dissociation constants. Tetranitromethane-modified HDL3 failed to bind to high-affinity specific binding sites and compete with 125I-HDL3 for binding. The results obtained make it possible to assume that, while apoA-I may be a determinant of the HDL receptor, the lipid composition of the lipoprotein may affect its interaction with the receptor.
研究了人高密度脂蛋白(HDL3)、载脂蛋白A-I(apoA-I)以及apoA-I与胆固醇和/或二肉豆蔻酰磷脂酰胆碱(DMPC)的重组体与分离的人小肠上皮细胞上HDL受体的结合情况。apoA-I竞争125I标记的HDL3结合位点的能力不如HDL3有效,且与细胞结合的125I标记的apoA-I量低于125I-HDL3。apoA-I/DMPC重组体竞争125I-HDL3结合位点的能力与HDL3相近,且125I-apoA-I/DMPC重组体与细胞结合的效率至少与125I-HDL3相同。apoA-I/DMPC/胆固醇重组体无法竞争125I-HDL3结合位点,且125I-apoA-I/DMPC/胆固醇复合物与细胞的结合比其他颗粒低几倍。所有颗粒与细胞结合的解离常数相似。四硝基甲烷修饰的HDL3无法与高亲和力特异性结合位点结合,也无法与125I-HDL3竞争结合。所得结果表明,虽然apoA-I可能是HDL受体的决定因素,但脂蛋白的脂质组成可能会影响其与受体的相互作用。